A Study of Zigakibart in Adults With IgA Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 383 participants.

Also called NCT05852938

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 383 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05852938
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, China, Croatia, Czechia, France, Germany, Greece, India, Israel, Italy, Japan, Malaysia, Mexico, South Korea, Spain, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05852938. Randomized; double masking; primary purpose treatment. Start 2023-07-06 (actual); primary completion 2027-08-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Zigakibart in Adults With IgA Nephropathy
Condition
IgA Nephropathy
Condition
Immunoglobulin A Nephropathy
Intervention (Drug)
BION-1301
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05852938
Content hash
e5cea313809c8a8ab66296f269cb467694c3cefd487c14ee329f7962a2a63491